Stockreport

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

Septerna, Inc.  (SEPN) 
PDF Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support [Read more]